ArticlePakistan journal of medical sciences2025
Clinical efficacy of the atropine and pralidoxime treatment combined with hemoperfusion in patients with acute organophosphate pesticide poisoning.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the clinical efficacy of hemoperfusion (HP) combined with atropine and pralidoxime treatment in patients with acute organophosphate pesticide poisoning (AOPP). Methodology: This retrospective analysis included clinical data of 64 patients with AOPP admitted to Yongkang First People's Hospital from October 2020 to January 2024. Among them, 32 patients were treated with atropine and pralidoxime (control group); 32 cases were treated with HP combined with atropine and pralidoxime (HP group). The primary outcomes were the required atropine conversion time, atropine dose, acetylcholinesterase (AchE) recovery time, Acute Physiology and Chronic Health Evaluation II (APACHE II) score at the time of atropine conversion, and in-hospital mortality rate. The secondary outcomes included changes in myocardial enzyme spectrum and inflammation levels. Results: The atropine conversion time, AchE recovery time, atropine dosage, and APACHE-II score during atropine conversion were significantly lower in the HP group than in the control group ( Conclusions: HP in combination with atropine and pralidoxime in the treatment of AOPP can achieve higher benefits during atropine conversion in terms of atropine conversion time, AchE recovery time, and atropine dosage and is associated with a better APACHE-II score. This regimen can significantly downregulate the expression of myocardial enzymes and inflammatory factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.